Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes (Q33389465)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Eva Hellström-Lindberg

5

object named as

Eva Hellström-Lindberg

0 references

Valeria Santini

object named as

Valeria Santini

6

0 references

2

object named as

Pierre Fenaux

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

John F Seymour

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lewis R Silverman

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ghulam J Mufti

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Eva Hellström-Lindberg

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Alan F List

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Steven D Gore

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jay Backstrom

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

David McKenzie

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

C L Beach

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

6 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Critical Reviews in Oncology Hematology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

76

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

218-227

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000027

21 June 2018

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000027

21 June 2018

Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000027

21 June 2018

Arsenic and old lace: novel approaches in elderly patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000027

21 June 2018

Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000027

21 June 2018

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000027

21 June 2018

Low dose Ara-C for myelodysplastic syndromes: is it still a current therapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000027

21 June 2018

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000027

21 June 2018

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000027

21 June 2018

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000027

21 June 2018

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000027

21 June 2018

A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000027

21 June 2018

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000027

21 June 2018

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000027

31 October 2018

A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000027

31 October 2018

Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000027

31 October 2018

Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000027

31 October 2018

Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000027

31 October 2018

The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20451404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/20451404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/20451404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20451404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20451404

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.CRITREVONC.2010.04.005

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33389465&oldid=1991106545"